

Angiolite Registry Study

NCT07004569

Status	RECRUITING
Sponsor	Chinese University of Hong Kong
Enrollment	55 participants

Key Eligibility Criteria

Inclusion (6)

- Subject age ≥ 18 .
- Subject (or legal guardian) understands the trial requirements and treatment procedures and provides written informed consent.
- Indication for a percutaneous coronary intervention (PCI) in native epicardial arteries involving left main coronary artery, including patients with stable coronary artery disease and acute coronary syndromes (non-ST-elevated myocardial infarction and ST-elevation myocardial infarction).
- Target lesion must have a stenosis of $\geq 50\%$ and $< 100\%$ angiographically.
- Target lesion must have an angiographic reference vessel diameter of 2.0-6.0 mm.

... and 1 more (see full listing online)

Exclusion (4)

- Known history of an allergic reaction or significant sensitivity to sirolimus or other analogue or derivative.
- Known history of an allergic reaction or significant sensitivity to fluoroacrylate or its analogue or derivative.
- Pregnant or breastfeeding woman.
- Currently participating in another device study that has not completed the primary end point or that clinically interferes with the current study endpoints.

Locations (1 total)

Prince of Wales Hospital, Hong Kong, Shatin, Hong Kong